INDEX

Declaration i
Preface ii
Acknowledgements iv
Appendix- I: List of Abbreviations vi
Appendix- II: List of Figures ix
Appendix- III: List of Tables xi

CHAPTER-I

1. Introduction 1

1.1. Diabetes 1

1.1.1. Types of diabetes 3

1.1.1.1. Type 1 diabetes mellitus (T1DM) 3

1.1.1.2. Type 2 diabetes mellitus (T2DM) 4

1.1.1.3. Gestational diabetes mellitus (GDM) 5

1.2. Pathogenesis of T2DM 6

1.3. Current & Newer therapies for the treatment of T2DM 7

1.3.1. Current therapies for the treatment of T2DM 7

1.3.1.1. Injectable therapies for the treatment of T2DM 8

1.3.1.2. Oral antidiabetic agents for the treatment of T2DM 11

1.3.2. Newer therapies for the treatment of T2DM 14

1.4. Introduction to PTP-1B inhibitors 22

1.4.1. Protein Phosphatase and their importance 22

1.4.2. Protein tyrosine phosphatase (PTPs) 24
1.4.3. Role of PTP-1B in metabolic diseases

1.4.3.1. PTP-1B as a negative regulator of insulin signaling

1.5. Crystal structure of PTP-1B

1.6. PTP-1B mechanism of action (MOA)

1.7. Challenges in developing potent and selective PTP-1B inhibitors

1.7.1. Identification of noncatalytic aryl phosphate-binding site

1.7.2. Identification of dual-binding site phosphotyrosine mimetics (pTyr mimetics)

1.8. Overview on PTP-1B inhibitors under development

1.9. Conclusion

1.10. References

CHAPTER-II

2. Design Strategy of PTP-1B inhibitors

2.1. Orally active, potent and selective PTP-1B inhibitors

2.1.1. Rationale for designing benzotriazole based PTP-1B inhibitors (First series)

2.1.2. Rationale for designing triaryl-sulfonamide based PTP-1B inhibitors (Second series)

2.1.3. Rationale for designing peptidomimetic based PTP-1B inhibitors (Third series)

2.1.4. Conclusion

2.1.5. References

CHAPTER-III

3. Results and discussion
3.1. Benzotriazole based PTP-1B inhibitors (First series) 79

3.1.1. Chemistry 79

3.1.2. In vitro PTP-1B inhibitory activity, selectivity and structure activity relationship (SAR) 92

3.1.3. In vivo (antidiabetic activity) evaluation of PTP-1B inhibitors 96

3.1.4. PK studies of selected compounds 97

3.1.5. Docking studies 98

3.1.6. Conclusion 100

3.2. Triaryl-sulfonamide based PTP-1B inhibitors (Second series) 101

3.2.1. Chemistry 101

3.2.2. In vitro PTP-1B inhibitory activity, selectivity and structure activity relationship (SAR) 110

3.2.3. In vivo (antidiabetic activity) evaluation of PTP-1B inhibitors 116

3.2.4. PK studies of selected compounds 117

3.2.5. Docking studies 118

3.2.6. Conclusion 119

3.3. Peptidomimetic based PTP-1B inhibitors (Third series) 120

3.3.1. Chemistry 120

3.3.2. In vitro PTP-1B inhibitory activity, selectivity and structure activity relationship (SAR) 134

3.3.3. Docking studies 139

3.3.4. Conclusion 141

3.4. References 142
CHAPTER-IV

4. Overall summary and Future prospects 145

CHAPTER-V

5. Experimental 151

5.1. Chemistry 151

5.2. Docking study 336

5.3. Biology 336

5.4. References 338

6. Appendix-IV: Spectra ($^1$HNMR, ESI-MS, $^{13}$C-NMR and HPLC of representative compounds) 340

7. Publications 405

8. Vitae 420